#VisualAbstract: Ubrogepant is safe and effective for acute treatment of migraine prodrome

1. Absence of moderate or severe headache 24 hours following administration of treatment drug was significantly greater among patients with migraine attacks that were treated with ubrogepant during the prodrome phase. 2. Adverse events were slightly more frequent in the ubrogepant group versus placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Ubrogepant, a calcitonin gene-related peptide […]

The post #VisualAbstract: Ubrogepant is safe and effective for acute treatment of migraine prodrome first appeared on 2 Minute Medicine.